Global Down Syndrome

Issue 2 of 4 2018

Issue link: https://viewer.e-digitaledition.com/i/1027058

Contents of this Issue

Navigation

Page 10 of 31

SCIENCE SNPs ISSUES WITH MUSCLE REGENERATION A new publication from the Linda Crnic Institute for Down Syndrome revealed defects in muscle regeneration after injury in a mouse model of Down syndrome. Using a chemical injury model commonly used to study the capacity of muscles to regenerate, scientists observed a failure of the stem cells of the muscle, known as "satellite cells," to expand and restore muscle mass after the injury. This impairment of satellite cell function, which was exacerbated as the mice aged, underscores stem cell deficiencies as a potential contributor to Down syndrome-associated co-morbidities. Future research will define the relationship between satellite cell malfunction and the common occurrence of hypotonia in people with Down syndrome. Pawlikowski, et al. Scientific Reports. 2018; 8(1):4309. LESSONS FROM ZIKA While it is well established that trisomy 21 causes immune dysregulation, including chronic activation of the anti-viral interferon response, little is known about how increased interferon signaling could affect embryonic development in the womb. Recently, scientists revealed a key role for the interferon response in the adverse fetal outcomes caused by Zika virus infection. They showed that IFNAR1, a key gene on chromosome 21 required to mount the interferon response, was necessary for the ill effects of Zika infection during embryonic development in mice. Although embryos completely lacking IFNAR1 were more susceptible to Zika infection, they fared better during development. In fact, they showed that the immune response to Zika, not the virus itself, inhibited placental development and impaired maternal-fetal communication. These results reinforce the notions that the exacerbated interferon signaling observed in people with Down syndrome could have negative impacts on development and that strategies to dampen interferon signaling could have therapeutic benefits. Yockey, et al. Science Immunology. 2018; 3(19):1680. models of Down syndrome completed by Lenny Maroun, Ph.D., currently at the Crnic Institute, demonstrated that reducing the Interferon response improves the development of these mice (Maroun et al., 2000). Altogether, this body of research justifies a strong investment in the study of the immune system in Down syndrome, with the obvious potential to develop diagnostic and therapeutic strategies to improve the well-being of those living with trisomy 21. To learn more about research at the Crnic Institute, visit globaldownsyndrome.org/our-story/linda-crnic-institute. References: Maroun, L.E., Heffernan, T.N., and Hallam, D.M. Partial IFN-alpha/ beta and IFN-gamma receptor knockout trisomy 16 mouse fetuses show improved growth and cultured neuron viability. Journal of Interferon & Cytokine Research: the Official Journal of the International Society for Interferon and Cytokine Research. 2000; 20, 197–203. Sullivan, K.D., Evans, D., Pandey, A., Hraha, T.H., Smith, K.P., Markham, N., Rachubinski, A.L., Wolter-Warmerdam, K., Hickey, F., Espinosa, J.M., et al. Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation. Scientific Reports. 2017; 7, 14,818. Sullivan, K.D., Lewis, H.C., Hill, A.A., Pandey, A., Jackson, L.P., Cabral, J.M., Smith, K.P., Liggett, L.A., Gomez, E.B., Galbraith, M.D., et al. Trisomy 21 consistently activates the interferon response. 2016; eLife. 5. GLOBALDOWNSYNDROME.ORG 11

Articles in this issue

Links on this page

Archives of this issue

view archives of Global Down Syndrome - Issue 2 of 4 2018